Anti-hyperuricemic and anti-inflammatory actions of vaticaffinol isolated from Dipterocarpus alatus in hyperuricemic mice.
10.1016/S1875-5364(17)30053-5
- Author:
Yu-Sheng CHEN
1
;
Chao-Jun CHEN
1
;
Wei YAN
1
;
Hui-Ming GE
2
;
Ling-Dong KONG
3
Author Information
1. Institute of Functional Biomolecules, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China.
2. Institute of Functional Biomolecules, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China. Electronic address: hmge@nju.edu.cn.
3. Institute of Functional Biomolecules, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, China. Electronic address: kongld@nju.edu.cn.
- Publication Type:Journal Article
- Keywords:
Anti-hyperuricemic effect;
Dipterocarpus alatus;
Kidney inflammation;
Kidney organic ion transporters;
Vaticaffinol
- MeSH:
Animals;
Anti-Inflammatory Agents;
administration & dosage;
Dipterocarpaceae;
chemistry;
Humans;
Hyperuricemia;
blood;
drug therapy;
immunology;
Interleukin-18;
genetics;
immunology;
Interleukin-1beta;
genetics;
immunology;
Interleukin-6;
genetics;
immunology;
Kidney;
drug effects;
immunology;
Male;
Mice;
Organic Anion Transport Protein 1;
genetics;
immunology;
Plant Extracts;
administration & dosage;
Stilbenes;
administration & dosage;
Tumor Necrosis Factor-alpha;
genetics;
immunology;
Uric Acid;
blood
- From:
Chinese Journal of Natural Medicines (English Ed.)
2017;15(5):330-340
- CountryChina
- Language:English
-
Abstract:
The present study was designed to examine the anti-hyperuricemic and anti-inflammatory effects and possible mechanisms of vaticaffinol, a resveratrol tetramer isolated from ethanol extracts of Dipterocarpus alatus, in oxonate-induced hyperuricemic mice. At 1 h after 250 mg·kg potassium oxonate was given, vaticaffinol at 20, 40, and 60 mg·kg was intragastrically administered to hyperuricemic mice once daily for seven consecutive days. Vaticaffinol significantly decreased serum uric acid levels and improved kidney function in hyperuricemic mice. It inhibited hepatic activity of xanthine dehydrogenase (XDH) and xanthine oxidase (XOD), regulated renal mRNA and protein levels of urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1), organic cation transporter 1 (OCT1), OCT2, organic cation/carnitine transporter 1 (OCTN1), and OCTN2 in hyperuricemic mice. Moreover, vaticaffinol markedly down-regulated renal protein levels of NOD-like receptor 3 (NLRP3), apoptosis-associated speck-like (ASC), and Caspase-1, resulting in the reduction of interleukin (IL)-1β, IL-18, IL-6 and tumor necrosis factor-α (TNF-α) levels in this animal model. Additionally, HPLC and LC-MS analyses clearly testified the presence of vaticaffinol in the crude extract. These results suggest that vaticaffinol may be useful for the prevention and treatment of hyperuricemia with kidney inflammation.
